Shire Agrees To Acquire NPS Pharmaceuticals

January 2015
Investors Business Daily;1/12/2015, p00
Anglo-Irish drugmaker


Related Articles

  • Shire acquires Canadian rights to five products from Draxis Health.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p24 

    Reports on the purchase agreement between Shire BioChem Inc. and Draxis Health Inc. over the rights of five products from Draxis Health. Terms under the agreement; Benefits of the deal for both companies; Significance of the agreement for the pharmaceutical biotechnology industry.

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;2/28/2004, Issue 990, p2 

    Reports on a letter issued by Shire BioChem Inc. advising of the possibility of pergolide-associated sudden-onset sleep during activities of daily living. Side effect of pergolide; Advice for physicians and patients taking pergolide.

  • Canadian Permax label change: risk of cardiac valvulopathy.  // Reactions Weekly;11/6/2004, Issue 1026, p2 

    Reports on a Dear HealthCare Professional letter and a Public Advisory issued by Shire BioChem Inc. concerning new safety information on Permax and the risk of cardiac valvulopathy. Sections of the Permax product monograph that will be revised; Contraindication of Permax, based on the new...

  • Adderall XR allowed back on the Canadian market.  // Reactions Weekly;9/3/2005, Issue 1067, p2 

    Reports on a decision by Health Canada to allow the drug Aderall XR from Shire BioChem Inc. back on the Canadian market, as of September 2005. Reason behind the suspension of the sale of the drug; Conditions for allowing the sale of the drug.

  • Shire: Adderall should recover from Canadian blow.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p18 

    The article reports that the government agency Health Canada is informing Canadians that it has ordered Shire BioChem Inc., the manufacturer of Adderall XR to withdraw the drug from the Canadian market. The agency has suspended the market authorization of the product due to safety information...

  • Revised labelling for Adderall XR in Canada.  // Reactions Weekly;9/10/2005, Issue 1068, p2 

    Reports on a Dear Health Care Professional letter issued by Shire BioChem Inc. advising that Adderall XR has returned to the Canadian market for the treatment of attention-deficit hyperactivity disorder (ADHD), and that the Canadian labeling of the drug will be revised. Adverse effect of...

  • 2004 Round-Up: 'Twas the Best of Times -- 'Twas the Worst of Times.  // BioPharm International;Dec2004, Vol. 17 Issue 12, p12 

    The article presents information on the best and the worst events that happened in pharmaceutical industry in the year 2004. While the overall stock market struggled in 2004, held back by uncertainty over the War in Iraq, the presidential elections, and the plummeting dollar, the Nasdaq Biotech...

  • Health Canada suspends Adderall, US FDA advises caution.  // Reactions Weekly;2/19/2005, Issue 1039, p2 

    Reports on the move by Health Canada to suspend the market authorization of the Adderall drug, developed and manufactured by Shire BioChem Inc. Use of the drug for the treatment of attention-deficit hyperactivity disorder; Claims of sudden deaths, heart-related deaths and strokes in children...

  • Inconclusive evidence puts Adderall back on the market. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p858 

    Reports on the reintroduction Adderall, an amphetamine for treating attention-deficit hyperactivity disorder from Shire Biochem Inc., in the drug market in Canada as of October 2005. Basis of Health Canada's decision to allow the reintroduction of the drug; Reason behind the pull-out of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics